Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

Diseases /

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

Back to Diseases List

Associated Genetic Biomarkers

ABL1
ABL1 Fusion
ABL2
ABL2 Fusion
BCR
BCR-ABL1
BCR-ABL1 Fusion
CRLF2
CRLF2 Fusion
CSF3R
CSF3R Mutation
EPOR
EPOR Fusion
FGFR1
FGFR1 Fusion
FGFR2
FGFR2 Fusion
FGFR3
FGFR3 Fusion
FGFR4

FGFR4 Fusion
FLT3
FLT3 Fusion
IDH1
IDH1 Mutation
IDH2
IDH2 Mutation
IKZF1
IKZF1 Frameshift
IKZF1 Nonsense

IL7R
IL7R Mutation
JAK1
JAK1 Fusion
JAK1 Loss
JAK1 Mutation
JAK2
JAK2 Fusion
JAK2 Mutation
JAK3

JAK3 Fusion
JAK3 Mutation
LYN
LYN Fusion
NTRK1
NTRK1 Fusion
NTRK2
NTRK2 Fusion
NTRK3
NTRK3 Fusion

PDGFRA
PDGFRA Fusion
PDGFRB
PDGFRB Fusion
PTL2B fusion
SH2B3
SH2B3 Loss
SH2B3 Mutation
TYK2
TYK2 Fusion

t(9;22)(q34;q11)

Overview

NCI Definition: A myelodysplastic/myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene. (WHO, 2001) [1]

Atypical chronic myeloid leukemia, BCR-ABL1 negatives most frequently harbor alterations in SRSF2, KIT, U2AF1, SETBP1, and IDH1 [2].

Most Commonly Altered Genes in Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

SRSF2 Mutation, SRSF2 Exon 1 Mutation, KIT Mutation, KIT Exon 17 Mutation, and KIT D816V are the most common alterations in atypical chronic myeloid leukemia, BCR-ABL1 negative [2].

Top Alterations in Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

Clinical Trials

View Clinical Trials for Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

There are 7 clinical trials for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 4 are open and 3 are completed or closed. Of the trials that contain atypical chronic myeloid leukemia, BCR-ABL1 negative as an inclusion criterion, 1 is early phase 1 (1 open), 3 are phase 1 (3 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open).

ABL1, ABL2, and CRLF2 are the most frequent gene inclusion criteria for atypical chronic myeloid leukemia, BCR-ABL1 negative clinical trials [3].

Trials Investigating Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative by Gene and Recruiting Status

Azacitidine, ruxolitinib, and decitabine are the most common interventions in atypical chronic myeloid leukemia, BCR-ABL1 negative clinical trials.

Drugs Being Investigated in Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative Trials by Recruiting Status

Significant Genes in Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

AFF1 +

AFF1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

CBFB +

CBFB is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains CBFB status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [3].

CSF3R +

CSF3R is altered in 25.0% of atypical chronic myeloid leukemia, BCR-ABL1 negative patients [2].

CSF3R is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains CSF3R status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 2 (0 open) [3].

ELL +

ELL is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains ELL status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH1 +

IDH1 is altered in 25.0% of atypical chronic myeloid leukemia, BCR-ABL1 negative patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH2 +

IDH2 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2A +

KMT2A is an inclusion eligibility criterion in 2 clinical trials for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (0 open) [3].

MECOM +

MECOM is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

MLF1 +

MLF1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT1 +

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT10 +

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT3 +

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT4 +

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

MYH11 +

MYH11 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [3].

NPM1 +

NPM1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

NRIP3 +

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

PML +

PML is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains PML status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [3].

RARA +

RARA is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains RARA status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [3].

RUNX1 +

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [3].

RUNX1T1 +

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains RUNX1T1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [3].

Disease Details

Synonyms

Subacute Myeloid Leukemia, Subacute Granulocytic Leukemia, Atypical CML, Atypical Chronic Myeloid Leukemia, Subacute Myelogenous Leukemia, aCML

Parent(s)

Myelodysplastic/Myeloproliferative Neoplasm

OncoTree Name

Atypical Chronic Myeloid Leukemia, BCR-ABL1-

OncoTree Code

ACML

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative

Disease Details

References

About

Molecular Medicine

Content Types